The present invention relates to a method for preparing acetate compounds using ketene.

The present invention relates to a method for preparing acetate compounds using ketene.

The present invention relates to a method for preparing acetate compounds using ketene.

A platform drug delivery system and a method of improving the delivery of low solubility pharmaceuticals utilizing crystal engineering and Theanine dissolution resulting in enhanced bioactivity, dissolution rate, and solid state stability.

A platform drug delivery system and a method of improving the delivery of low solubility pharmaceuticals utilizing crystal engineering and Theanine dissolution resulting in enhanced bioactivity, dissolution rate, and solid state stability.

Compounds having a structure of formula (I), (I-A), (Ia)-(Ie), (A)-(E), and (II) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of disorders including prostate cancer are also provided.

The present invention relates to a process for preparing Lomitapide or its pharmaceutically acceptable salt thereof having high purity with acceptable levels of impurities.

The present invention relates to a process for preparing Lomitapide or its pharmaceutically acceptable salt thereof having high purity with acceptable levels of impurities.

The present invention relates to a process for preparing Lomitapide or its pharmaceutically acceptable salt thereof having high purity with acceptable levels of impurities.

A racemic or optically enriched compound of Formula 1:

##STR00001## wherein P is H or a protective group for hydroxyl groups; and X is Cl, Br, I, or CH.sub.2CH.sub.2CH.sub.2COOR.sub.1, wherein R.sub.1 is C.sub.1-7-alkyl or C.sub.7-11-aralkyl.